Type 1 narcolepsy is caused by a loss of hypocretin (orexin) signaling in the brain. Genetic data suggests the disorder is caused by an autoimmune attack on hypocretin producing neurons in hypothalamus. This hypothesis has however not yet been confirmed by consistent findings of autoreactive antibodies or T-cells in patient samples. One explanation for these negative results may be that the autoimmune process is no longer active when patients present to the clinic. With increasing awareness in recent years, more and more patients have been diagnosed closer and closer to disease onset. In this study, we tested whether an active immune process in the brain could be detected in these patients, as reflected by increased cytokine levels in the cerebrospinal fluid (CSF). Using multiplex analysis, we measured the levels of 51 cytokines and chemokines in the CSF of 40 type 1 narcolepsy patients having varying disease duration. For comparison, we used samples from 9 healthy controls and 9 patients with other central hypersomnia. Cytokine levels did not differ significantly between controls and patients, even in 5 patients with disease onset less than a month prior to CSF sampling.

B. R. Kornum, F. Pizza, S. Knudsen, G. Plazzi, P. Jennum, E. Mignot (2015). Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. BRAIN BEHAVIOR AND IMMUNITY, 49, 54-58 [10.1016/j.bbi.2015.03.004].

Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset.

PIZZA, FABIO;PLAZZI, GIUSEPPE;
2015

Abstract

Type 1 narcolepsy is caused by a loss of hypocretin (orexin) signaling in the brain. Genetic data suggests the disorder is caused by an autoimmune attack on hypocretin producing neurons in hypothalamus. This hypothesis has however not yet been confirmed by consistent findings of autoreactive antibodies or T-cells in patient samples. One explanation for these negative results may be that the autoimmune process is no longer active when patients present to the clinic. With increasing awareness in recent years, more and more patients have been diagnosed closer and closer to disease onset. In this study, we tested whether an active immune process in the brain could be detected in these patients, as reflected by increased cytokine levels in the cerebrospinal fluid (CSF). Using multiplex analysis, we measured the levels of 51 cytokines and chemokines in the CSF of 40 type 1 narcolepsy patients having varying disease duration. For comparison, we used samples from 9 healthy controls and 9 patients with other central hypersomnia. Cytokine levels did not differ significantly between controls and patients, even in 5 patients with disease onset less than a month prior to CSF sampling.
2015
B. R. Kornum, F. Pizza, S. Knudsen, G. Plazzi, P. Jennum, E. Mignot (2015). Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. BRAIN BEHAVIOR AND IMMUNITY, 49, 54-58 [10.1016/j.bbi.2015.03.004].
B. R. Kornum;F. Pizza;S. Knudsen;G. Plazzi;P. Jennum;E. Mignot
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/511779
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 27
social impact